Advertisement

Digestive Diseases and Sciences

, Volume 51, Issue 11, pp 1904–1909 | Cite as

A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms

  • Edoardo G. Giannini
  • Patrizia Zentilin
  • Pietro Dulbecco
  • Elena Iiritano
  • Claudio Bilardi
  • Edoardo Savarino
  • Carlo Mansi
  • Vincenzo SavarinoEmail author
Original Paper

Abstract

The aims of the present study were to compare effects of sodium alginate and the antacid magaldrate anhydrous in adults with gastroesophageal reflux (GOR) symptoms.

Patients with heartburn and/or acid regurgitation for at least 3 days in the week before the study started (n=203) were randomized to receive a single dose of sodium alginate or magaldrate anhydrous at the onset of symptoms during a 3-day run-in period. Patients with symptoms during the run-in (n=191) were rerandomized to receive a 14-day treatment with either drug given as four daily doses. A speed of action ≤30 min was significantly more frequent among patients in the alginate group (49.4% vs. 40.4%; P=0.0074). A trend toward a more prolonged duration of action (median: 16.5 vs. 12.7 hr) and a greater sum of the symptom intensity difference (median: 40.0 vs. 31.0) was observed in the sodium alginate group. Total disappearance of symptoms was reported in 81.6% and 73.9% of patients in the sodium alginate group and magaldrate group, respectively. We conclude that sodium alginate was faster than magaldrate in relieving GRO symptoms and showed a tendency toward a more prolonged duration of action and a higher level of efficacy.

Keywords

Sodium alginate Magaldrate Heartburn Acid regurgitation 

Notes

Acknowledgments

This study was supported by Novartis Consumer Health SpA, Italy.

References

  1. 1.
    Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ (2003) The burden of illness of gastroesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 17:1309–1317PubMedCrossRefGoogle Scholar
  2. 2.
    Joish VN, Donaldson G, Stockdale W, Oderda GM, Crawley J, Sasane R, Joshua-Gotlib S, Brixner DI (2005) The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin 21:535–544PubMedCrossRefGoogle Scholar
  3. 3.
    Valle C, Broglia F, Pistorio A, Tinelli C, Perego M (1999) Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease. Dig Dis Sci 44:1848–1852PubMedCrossRefGoogle Scholar
  4. 4.
    Niemcryk SJ, Joshua-Gotlib S, Levine DS (2005) Outpatient experience of patients with GERD in the United States: analysis of the 1998–2001 National Ambulatory Medical Care Survey. Dig Dis Sci 50:1904–1908PubMedCrossRefGoogle Scholar
  5. 5.
    Okamoto K, Iwakiri R, Mori M, Hara M, Oda K, Danjo A, Ootani A, Sakata H, Fujimoto K (2003) Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci 48:2237–2241PubMedCrossRefGoogle Scholar
  6. 6.
    Chatfield S (1999) A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastroesophageal reflux disease. Curr Med Res Opin 15:152–159PubMedCrossRefGoogle Scholar
  7. 7.
    Zentilin P, Dulbecco P, Savarino E, Parodi A, Iiritano E, Bilardi C, Reglioni S, Vigneri S, Savarino V (2001) An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Aliment Pharmacol Ther 21:29–34CrossRefGoogle Scholar
  8. 8.
    Washington N, Steele RJ, Jackson SJ, Washington C, Bush D (1998) Patterns of food and acid reflux in patients with low-grade oesophagitis—the role of an anti-reflux agent. Aliment Pharmacol Ther 12:53–58PubMedCrossRefGoogle Scholar
  9. 9.
    Mandel KG, Daggy BP, Brodie DA, Jacoby HI (2000) Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 14:669–690PubMedCrossRefGoogle Scholar
  10. 10.
    Korman MG, Nicholson L, Chan JG (1990) In-vivo anti-reflux and raft properties of alginates. Aliment Pharmacol Ther 4:615–622PubMedGoogle Scholar
  11. 11.
    Marciani L, Little SL, Snee J, Coleman NS, Tyler DJ, Sykes J, Jolliffe IG, Dettmar PW, Spiller RC, Gowland PA (2002) Echo-planar magnetic resonance imaging of Gaviscon alginate rafts in-vivo. J Pharm Pharmacol 54:1351–1356PubMedCrossRefGoogle Scholar
  12. 12.
    Hampson FC, Farndale A, Strugala V, Sykes J, Jolliffe IG, Dettmar PW (2005) Alginate rafts and their characterisation. Int J Pharm 294:137–147PubMedCrossRefGoogle Scholar
  13. 13.
    Taylor G, Warren SJ, Kelleway IW, Patel B, Little SL (1997) Gastric residence of Gaviscon Advance and Liquid Gaviscon in healthy volunteers. J Pharm Pharmacol 49(Suppl 4):73 (131)Google Scholar
  14. 14.
    Chevrel B (1980) A comparative crossover study on the treatment of heartburn and epigastric pain: Liquid Gaviscon and a magnesium-aluminium antacid gel. J Int Med Res 8:300–302PubMedGoogle Scholar
  15. 15.
    Juul-Hansen P, Rydning A (2003) Endoscopy-negative reflux disease: What is the value of a proton-pump inhibitor test in everyday clinical practice? Scand J Gastroenterol 38:1200–1203PubMedCrossRefGoogle Scholar
  16. 16.
    Numans ME, Lau J, de Wit NJ, Bonis PA (2004) Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140:518–527PubMedGoogle Scholar
  17. 17.
    Orr WC (2004) Sleep and gastroesophageal reflux disease: a wake-up call. Rev Gastroenterol Disord 4(Suppl 4):S25–S32PubMedGoogle Scholar
  18. 18.
    Gislason T, Janson C, Vermeire P, Plaschke P, Bjornsson E, Gislason D, Boman G (2002) Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries. Chest 121:158–163PubMedCrossRefGoogle Scholar
  19. 19.
    Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, Revicki D (2001) The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 161:45–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Edoardo G. Giannini
    • 1
  • Patrizia Zentilin
    • 1
  • Pietro Dulbecco
    • 1
  • Elena Iiritano
    • 1
  • Claudio Bilardi
    • 1
  • Edoardo Savarino
    • 1
  • Carlo Mansi
    • 1
  • Vincenzo Savarino
    • 1
    Email author
  1. 1.Cattedra di Gastroenterologia, Dipartimento di Medicina InternaUniversità degli Studi di GenovaGenoaItaly

Personalised recommendations